IRCT20200105046010N91招募中Unknown
Bioequivalence study of Dutasteride/tamsulosin 0.5/0.4 mg capsule manufactured by Tasnim Co versus originator brand (Jalyn) manufactured by (GlaxoSmithCline plc (GSK) in fasting condition in healthy volunteers
Tasnim company0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcoholism and Narcoticism
- •History of allergy to Dutasteride and tamsulosin
研究者
相似试验
尚未招募
不适用
Study of absorption and elimination rate of Dutasteride capsules 0.5 mg in comparison with Dutasteride brand capsules (Avodart ®).IRCT20200407046981N33Zahravi pharmaceutical company24
已完成
不适用
Α Prospective Observational Study for the Evaluation of Disease Control and Quality of Life in Patients With Benign PROStatic hyPERplasia Under Fixed Dose combΙnaTion Treatment With Dutasteride and Tamsulosin . PROSPERITY Group of Studies (I&II)Benign Prostatic HyperplasiaNCT04831476Elpen Pharmaceutical Co. Inc.1,296
招募中
不适用
Clinical study to compare the in vivo parameters of 2 Tamsulosin 0.4 mg ER Capsule formulationsIRCT20180620040164N28Cosar pharmaceutical Co.24
已完成
不适用
Clinical study to compare the in vivo parameters of 2 Tamsulosin 0.4 mg ER Capsule formulationsIRCT20180620040164N26Dorsa Pharmaceutical Co.24
已完成
1 期
Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin Hydrochloride (HCL) Combination Capsule in Fasted StateUrologic DiseasesNCT02052713GlaxoSmithKline78